R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

How pharma companies can build mutually beneficial relations...

Seemingly every week, headlines declare new partnerships inked between global pharma giants and previously unknown start-ups.

R&D

Weight loss gold rush: Developers vie for next blockbuster t...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.

R&D

A doctor consults the prescription on his tablet and delivers drugs

Mpox shows need for new approaches to therapeutic antibody r...

Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health Organization (WHO) to declare a public health emergency.

R&D

Advancements in early detection and innovative therapies tar...

Alzheimer’s disease (AD) robs millions of individuals of their memories, cognitive function, and independence, placing an immense emotional and financial burden on families and healthcare s

R&D

LSX USA Jonah Comstock and Eloise McLennan Wrapup

Investment outlook: Key takeaways from LSX USA

Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies.

R&D

Richard Young, Nicole Raleigh, Daniel Schwenk and Andrea Kloeble

Boehringer Ingelheim and Veeva: A data partnership for One M...

Boehringer’s Medicine Excellence initiative harnesses technology with the aim to build a ‘One Medicine Platform’, unifying development processes and data in a centralised platform.